Skip to content

CFH-dependence hypotheses for upstream-CP0 candidates

Verdict

Rosmarinic acid, luteolin, exact Houttuynia cordata polysaccharide materials, and two Helicteres angustifolia lignans each have preclinical anti-complement evidence. Parts of their reported activity occur at complement nodes other than CFH, making retained activity under impaired CFH function plausible. None has been tested in the matched CFH-replete versus CFH-depleted MSU system needed to establish CFH independence, and no carrier-specific effect in gout has been demonstrated.

This literature synthesis therefore preserves four candidate-specific mechanism hypotheses and a shared experimental design. It is not a computational result, does not classify the candidates as CFH-independent, does not predict a genotype-response direction, and does not rank them for clinical use.

Evidence and unresolved leap

Candidate and exact-material boundary Grounded evidence What can be imagined without overstating it Missing observation
Rosmarinic acid Sahu 1999 reports covalent attachment to the activated C3b α′-chain and a 34 µM half-maximal concentration for inhibiting covalent C3b attachment to cells. The value and mechanism wording are verified against the PubMed abstract; the primary full text remains unresolved. [In Vitro; PubMed-abstract verified, full primary text unresolved] Englberger 1988 and Peake 1991 separately report C3- and C5-convertase effects. [In Vitro; abstract-level provenance] A C3b-directed biochemical effect may persist when CFH is absent or impaired. [Mechanistic Extrapolation] This is a hypothesis about a step in the cascade, not proof of net CFH independence. Exact rosmarinic acid in matched CFH-replete and CFH-depleted MSU-activated serum, with C3 fragment and C5a readouts.
Luteolin Zhang 2008 measured CH50 0.19 mM and AP50 0.17 mM in different whole-pathway hemolysis formats. [In Vitro; full-text verified] Similar CP/AP values do not localize the target and do not exclude CFH involvement. Activity in both pathway formats motivates testing a shared or multi-node mechanism that could retain some effect without CFH. [Mechanistic Extrapolation] Exact luteolin in the same matched serum system; target localization if activity survives.
CHCP and other named Houttuynia polysaccharide fractions Lu 2018 mapped exact CHCP activity by complement-depleted-serum rescue mainly to C3 and C4, with partial C5 involvement. [In Vitro; full-text verified] Xu 2015 and Lu 2018 report anti-inflammatory effects in non-gout lung-injury models using related but non-identical materials. [Animal Model] Activity at C4 or other non-CFH nodes makes a CFH-independent component plausible, but it does not establish the net behavior of an exact polysaccharide fraction in MSU-activated serum. [Mechanistic Extrapolation] One qualified fraction at a time in matched serum; no inference across HCP, HCPM, CHCP, or HCP-1 without material comparability.
Machicendonal and (7S,8R)-dihydrodehydrodiconiferyl alcohol from H. angustifolia Yin 2016 reports CH50/AP50 values of 40/105 µM for compound 4 and 9/21 µM for compound 5, with depletion-rescue mapping to several complement components. [In Vitro; full-text verified] This is a single-paper anchor. The reported multi-node pattern could include activity that does not require CFH. [Mechanistic Extrapolation] Independent matched-material replication before mechanistic or translational prioritization, followed by the matched CFH experiment.

The rosmarinic-acid record does not support a precise residue assignment here; the verified abstract localizes covalent attachment to the activated C3b α′-chain. The luteolin whole-pathway result cannot by itself distinguish direct complement-protein binding, convertase effects, CFH involvement, or assay-specific behavior.

Research conjecture — CFH impairment may expose a candidate-specific upstream complement opportunity

Grounded premises: CFH regulates alternative-pathway amplification on C3b-containing surfaces. [Mechanistic Extrapolation; complement-c5a-gout.md] Rosmarinic acid has C3b-directed biochemical evidence; luteolin inhibits CP and AP hemolysis; exact Houttuynia and Helicteres materials have depletion-rescue evidence at multiple complement nodes. [In Vitro; sources above]

Novel leap: One or more exact candidates may retain useful suppression of MSU-driven C5a when CFH function is reduced. No direct evidence tests this connection, and the candidates need not share the same answer.

Why it matters: A retained effect would reveal an upstream complement exploit that is not held hostage by normal CFH regulation and could identify a genotype-relevant experimental track.

Discriminating observation: Compare each exact material in CFH-replete and CFH-depleted MSU-activated serum, measuring C3 fragments and C5a with matched vehicle, restoration, and assay-interference controls.

Sourcing, delivery, and exposure boundary

The mechanism experiment requires chemically identified small molecules or a qualified polysaccharide fraction; plant names and food-frequency categories are not substitutes. Houttuynia fractions are not interchangeable, and the two Helicteres compounds require independent replication before exposure work.

Even a positive serum result would not establish that dietary or oral administration reaches an operative concentration at an MSU-driven compartment. That next question requires route-specific exposure measurement. Conversely, a diet-by-genotype association tests the recorded dietary proxy in that population. It cannot establish or retire the biochemical effect of an exact compound or fraction because material identity, dose, absorption, adherence, and compartment exposure are not matched.

Discriminating experiment

For each candidate that clears exact-material sourcing:

  1. Run a concentration series in CFH-replete serum, CFH-depleted serum, and depleted serum restored with purified CFH.
  2. Activate complement with MSU crystals under identical serum and crystal conditions.
  3. Measure C5a plus a proximal C3 readout; include vehicle, positive complement-inhibition, no-MSU, and assay-interference controls.
  4. Treat each candidate-material pair independently. Retained inhibition in depleted serum would support a CFH-independent component; loss of inhibition with restoration-sensitive behavior would support CFH dependence; ambiguous or non-monotonic behavior redirects the mechanism map.
  5. Bound every conclusion to the tested material, concentration range, matrix, and endpoint. A negative result kills that tested configuration, not every candidate or every upstream-complement strategy.

Donor-genotype serum can be a later validation layer, but it does not replace the controlled depletion-and-restoration experiment. A CFH Y402H × exposure × gout analysis remains hypothesis-generating and must not carry a biochemical retirement rule.

Current decision

  • Advance: exact-material sourcing and the matched CFH depletion/restoration assay for the candidates that are practical to obtain.
  • Replicate first: the two Helicteres compounds.
  • Do not infer: carrier benefit, null response, harm, dietary efficacy, cross-material equivalence, or a cross-candidate potency ranking.
  • Do not retire from population proxies: biobank results update only the tested exposure-proxy and population hypothesis.